RxDoctor Payments Data

Victor Guerrero, MD

Internal Medicine · Santa Maria, CANPI 1972596963

Payments from drug & device makers

$851in general payments, 2019–2025

Across 27 payments — averaging $31.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$277
  • GSK$259
  • Viiv Healthcare Company$129
  • Boehringer Ingelheim$93
  • Lilly USA, LLC$29
  • Novo Nordisk$28
  • plus $37 from 2 others

What the payments were for

  • Food & beverage$851100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$851 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$4,070
Medicare patients
251
Services billed
453

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate96$105,742
FarxigaDapagliflozin Propanediol72$80,603
JardianceEmpagliflozin31$29,797
XareltoRivaroxaban24$23,165
EliquisApixaban29$20,417
TradjentaLinagliptin18$16,008
JentaduetoLinagliptin/Metformin Hcl26$13,256
TrulicityDulaglutide12$11,446
LinzessLinaclotide12$6,446
InvokanaCanagliflozin13$6,242
ShingrixVaricella-Zoster Ge/As01b/Pf28$6,220
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$3,230
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$3,225
Losartan Potassium415$2,984
Levothyroxine Sodium224$2,674

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$277$105,74296 claims
AstraZenecaFarxiga$13$80,60372 claims
Boehringer IngelheimJardiance, Tradjenta, Jentadueto$93$59,06175 claims
PfizerEliquis$24$20,41729 claims
Lilly USA, LLCTrulicity$29$11,44612 claims
GSKShingrix$259$6,22028 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Santa Maria

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →